yahoo_financeOriginal article
Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward?
Phase 2negativeNegative
AI Analysis
Summary
Connect Biopharma's asthma drug candidate failed to meet a key trial endpoint. The outcome raises questions about the program's viability and regulatory pathway forward.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
missed key trial goal
Importance:6/10
Sentiment:
-0.80
asthmatrial failureclinical developmentdrug efficacy
Related Companies
Read the original article
Published by yahoo_finance on September 22, 2026 11:45 PM